CytoMed Therapeutics Limited (GDTC) has released an update.
CytoMed Therapeutics Limited has successfully dosed the first patient in its groundbreaking Phase I clinical trial, ANGELICA, which explores the potential of allogeneic CAR-gamma delta T cell therapy for treating advanced cancers. This innovative approach aims to improve accessibility and reduce costs by using donor-derived cells, marking a significant milestone for the company. Investors may find this development intriguing as it could reshape the landscape of cancer treatment.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.